Insmed reported $-83833000 in EBIT for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Acelrx Pharmaceuticals ACRX:US $ -9664000 420K
Alexion Pharmaceuticals ALXN:US $ 816.7M 185.9M
Alimera Sciences ALIM:US $ -2235000 2.41M
Arena Pharmaceuticals ARNA:US $ -131993000 3.31M
Biomarin Pharmaceutical BMRN:US $ 13.86M 13.56M
Cytokinetics CYTK:US $ -40611000 4.2M
Dynavax Technologies DVAX:US $ 29.01M 40.65M
Flexion Therapeutics FLXN:US $ -23141000 8.84M
Gilead Sciences GILD:US $ 2901M 250M
Insmed INSM:US $ -83833000 10.7M
Mirati Therapeutics MRTX:US $ -132421000 26.09M
Novartis NVS:US 3.4B 415M
Regeneron Pharmaceuticals REGN:US $ 1112.7M 54.3M
Sarepta Therapeutics SRPT:US $ -141865000 28.85M
Seattle Genetics SGEN:US $ -122420000 287.41M
Ultragenyx Pharmaceutical RARE:US $ -106569000 10.49M
Vertex Pharmaceuticals VRTX:US $ 883.93M 137.63M